Metastatic primary anorectal melanoma developing in a patient treated for multicentric glioblastoma multiforme: two rare malignancies presenting in synchronicity

Irfan Ahmad,1 Irfan Bashir,1 Neeraj Dhingra,1 Vijay Hangloo2

DESCRIPTION
A 66-year-old woman presented with complaints of dizziness, headache and forgetfulness, which had been worsening over the last 2 months. General physical examination revealed weakness in the left upper and lower limbs (power 4/5) with spasticity (deep tendon reflexes 3+ on left side). A non-contrast MRI brain revealed a mass lesion involving the right thalamus and another lesion in the right cerebellar peduncle. Both lesions were hyperintense on T2 and hypointense on T1 sequences (Figure 1).

Figure 1 Pretreatment non-contrast MRI images of multicentric glioma. (A) T1-weighted axial image reveals a hypointense space-occupying lesion in the right thalamus involving the right basal ganglia (red arrow). (B) T1-weighted axial image reveals a hypointense space-occupying lesion in the right middle cerebellar peduncle (blue arrow). (C, D) T2-weighted axial image reveals the heterogeneously hyperintense nature of the lesions involving the right thalamus (yellow arrow) and right middle cerebellar peduncle (green arrow). Note the relative lack of extensive perilesional oedema. (E, F) T2-weighted sagittal and coronal images demonstrate the discontinuity of both lesions, the right thalamic lesion located supratentorially (yellow arrow) and the right middle cerebellar peduncle lesion located infratentorially (green arrow).

Figure 2 Treatment planning images. (A, B) Dose colour wash in the axial and coronal planes with the lower limit set to 95% of 46 Gy. The planning target volume (PTV_46) was created by expanding the clinical target volume (CTV_46) by 3 mm, as per our institutional protocol for image-guided treatment delivery. Note that the PTV for this dose level has been allowed to extend into the brainstem (blue arrow). The planning parameter was volume receiving 95% (V_95%) of the prescribed dose (46 Gy) should be more than 98%. In this patient, the PTV_46V_95% was 100%. (C, D) Dose colour wash in the axial and coronal planes with the lower limit set to 95% of 60 Gy. Note that the PTV for this dose level has been cropped from the brainstem (black arrow) to permit sparing of the brainstem. The planning parameter was to achieve maximum dose received by 1 cc (D_1cc) of the brainstem to be less than 59 Gy. In this patient, the D_1cc of the brainstem was 58.1 Gy.

To cite: Ahmad I, Bashir I, Dhingra N, et al. BMJ Case Rep Published Online First: [please include Day Month Year]. doi:10.1136/bcr-2017-223450

Images in...
and delivery were performed on Varian Eclipse to respect the tolerance of the brainstem. Treatment planning was deliberately underdosed so as to respect the tolerance of the brainstem. Treatment planning and delivery were performed on Varian Eclipse v3.13 and Varian TrueBeam v2.5, respectively (Varian Medical Systems, Palo Alto, California, USA). Daily image guidance was performed with pretreatment cone beam CT or kV planar verification. The patient tolerated treatment well without any interruptions. One month post-treatment completion, her symptoms started to resolve. She was advised to continue adjuvant temozolomide (150 mg/m²) monthly, and a repeat MRI brain done at 2 months post-treatment revealed stable disease with reduction of perilesional oedema.

A month later, she consulted a general surgeon for complaints of foul-smelling discharge per rectum and mass protruding from the anus. On examination, she was diagnosed with grade III internal haemorrhoids and note was made of blackish discoloration on its surface (figure 3). Wide local excision was performed and the excised specimen was sent for histopathological evaluation, which revealed primary anorectal melanoma. A staging whole-body fluorodeoxyglucose positron emission tomography-CT (¹⁸F PET-CT) revealed metastatic dissemination (multiple hepatic lesions, perirectal and presacral lymph nodes) (figure 3). The patient was planned for immunotherapy with intravenous nivolumab 240 mg every 2 weeks and she received 4 cycles of the same. A week after the fourth cycle of nivolumab, the patient had a myocardial infarction and succumbed to it. The cause of death was deemed to be unrelated to cancer or its treatment. The case was discussed in our institutional multidisciplinary mortality meeting, and keeping in mind the advanced stage of melanoma at presentation, it was deemed that it likely developed synchronously with the multicentric glioma.

Multicentric gliomas are a rare entity, accounting for 2%–16% of all gliomas. Primary anorectal melanoma is also an exceedingly rare entity, accounting for 1% of all melanomas. To the best of our knowledge, this is the first reported instance of these two malignancies developing in a synchronous manner.

**Learning points**

- Multicentric glioma, being a rare entity, is a diagnosis of exclusion, and distinction needs to be made between multifocal and multicentric gliomas.
- Primary anal melanoma is also an exceedingly rare entity and has a poor prognosis, with limited therapeutic options.
- Symptoms arising in another organ system in patients with glioblastoma multiforme should be investigated thoroughly and managed expeditiously, to maximise quality of life.

**Contributors** IA is the treating junior consultant (radiotherapy), author of the paper, responsible for drafting the manuscript and revising it. He is the guarantor. IB is the supervising treating consultant (radiotherapy) and participated in article formulation, editing and oversight. ND is the treating resident (radiotherapy) and participated in article formulation and editing. VH is the supervising treating consultant (radiation oncology) and participated in article formulation, editing and oversight.

**Funding** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent** Obtained.

**Provenance and peer review** Not commissioned; externally peer reviewed.

© BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

**REFERENCES**


